title: A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis.
abstract: The objective of this pilot study was to determine whether 15 days of dietary supplementation with calcium fructoborate could acutely modulate inflammatory and lipid blood markers in individuals diagnosed with primary osteoarthritis. During 2 weeks, a placebo-controlled, randomized, double-blind study was conducted on 116 subjects that were initially recruited. Seventy-two subjects started the study, being divided into four groups, and only 60 completed the study as designed. The aim was to compare the effects of calcium fructoborate to placebo on subjects diagnosed with knee primary osteoarthritis. The obtained outcomes were inflammation biomarkers (C-reactive protein, fibrinogen, and erythrocyte sedimentation rate) and lipid markers (triglycerides, total cholesterol, LDL cholesterol, and HDL cholesterol). No serious adverse events were reported. The calcium fructoborate showed beneficial effect on the inflammatory markers for all groups subjected to the treatment when compared with the placebo group and slight changes in the lipid metabolism. This study suggests that short-term (2 weeks) calcium fructoborate supplementation in patients with osteoarthritis symptoms has a favorable prognosis on inflammation diseases.
authors: Biochemistry Department, University of Craiova, 13 A.I. Cuza Street, 200585, Craiova, Dolj, Romania. romulus_ion@yahoo.com
authors: Romulus
authors: R
authors: Scorei
authors: Paul
authors: P
authors: Mitrut
authors: Iulian
authors: I
authors: Petrisor
authors: Iulia
authors: I
authors: Scorei
references: Ann Rheum Dis. 2000 Jan;59(1):71-4
references: 10627432
references: Thromb Haemost. 1979 Apr 23;41(2):309-13
references: 473114
references: Arthritis Rheum. 1997 Apr;40(4):723-7
references: 9125256
references: Baillieres Clin Rheumatol. 1994 Aug;8(3):531-52
references: 7525084
references: Clin Biochem. 1999 Mar;32(2):113-7
references: 10211627
references: Semin Arthritis Rheum. 1995 Oct;25(2):75-86
references: 8578314
references: Bone. 1996 Feb;18(2):151-7
references: 8833209
references: Ann Rheum Dis. 2004 Apr;63(4):408-14
references: 15020335
references: Biol Trace Elem Res. 2011 Dec;143(3):1223-38
references: 21274653
references: Br J Nutr. 2007 Sep;98(3):571-5
references: 17419890
references: Biol Trace Elem Res. 2007 Jul;118(1):27-37
references: 17848728
references: Prev Med. 2006 Nov;43(5):368-71
references: 16908056
references: Biol Trace Elem Res. 2005 Nov;107(2):127-34
references: 16217137
references: Anticancer Agents Med Chem. 2010 May;10(4):346-51
references: 19912103
references: Environ Health Perspect. 1994 Nov;102 Suppl 7:83-5
references: 7889887
references: J Diet Suppl. 2009;6(3):211-26
references: 22435474
references: Arthritis Res. 2002;4(5):R5
references: 12223108
references: Biol Trace Elem Res. 2010 Jun;135(1-3):334-44
references: 19669712
references: Rev Rhum Engl Ed. 1998 Dec;65(12):759-65
references: 9923044
references: Front Biosci (Schol Ed). 2011 Jan 01;3:205-15
references: 21196370
references: Environ Health Perspect. 1994 Nov;102 Suppl 7:59-63
references: 7889883
references: J Rheumatol. 1997 Aug;24(8):1486-8
references: 9263139
references: Arthritis Res Ther. 2009;11(6):R181
references: 19961577
references: Clin Biochem. 1990 Dec;23(6):477-88
references: 2289305
references: Clin Biochem. 2005 Nov;38(11):981-6
references: 16150434
references: Rheumatology (Oxford). 2001 Jun;40(6):703-4
references: 11426032
references: Am J Manag Care. 2002 Oct;8(15 Suppl):S383-91
references: 12416788